TOLLIP and renal cell adenocarcinoma: Considering that autophagy inhibitors enhance the properties of currently used second-line agents, such as PD-L1 and mTOR inhibitors, TOLLIP seems to emerge not only as a prognostic factor but also as a potential therapeutic target in renal cell cancer.